Invesco
CADL icon

Invesco’s Candel Therapeutics CADL Stock Holding History

Invesco’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$102K Buy
20,907
+5,868
+39% +$31.9K ﹤0.01% 3623
2025
Q4 		$85K Buy
15,039
+3,380
+29% +$18.2K ﹤0.01% 3652
2025
Q3 		$59.5K Buy
11,659
+402
+4% +$2.32K ﹤0.01% 3735
2025
Q2 		$57K Buy
11,257
+844
+8% +$4.34K ﹤0.01% 3712
2025
Q1 		$58.8K Buy
+10,413
New +$85.1K ﹤0.01% 3686

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco's CADL Position: Q1 2026 in Review

Invesco increased its Candel Therapeutics (CADL) stake by 39% in Q1 2026, buying an estimated $31.9K and bringing the position to 20,907 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

Invesco first reported a position in CADL in Q1 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Invesco held 20,907 shares of Candel Therapeutics worth $102K as of Q1 2026.
  • Invesco bought 5,868 Candel Therapeutics shares in Q1 2026, an estimated $31.9K.
  • Candel Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3623 holding.
  • Invesco first reported a position in Candel Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.